ReNeuron Group (LSE:RENE) Days Payable : 0.00 (As of Sep. 2023)

View and export this data going back to 2005. Start your Free Trial

What is ReNeuron Group Days Payable?

ReNeuron Group's average Accounts Payable for the six months ended in Sep. 2023 was £1.99 Mil. ReNeuron Group's Cost of Goods Sold for the six months ended in Sep. 2023 was £0.00 Mil.

The historical rank and industry rank for ReNeuron Group's Days Payable or its related term are showing as below:

LSE:RENE's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 147.95
* Ranked among companies with meaningful Days Payable only.

ReNeuron Group's Days Payable stayed the same from Sep. 2022 (0.00) to Sep. 2023 (0.00).

ReNeuron Group Days Payable Historical Data

The historical data trend for ReNeuron Group's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Days Payable Chart

ReNeuron Group Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Days Payable

Get a 7-Day Free Trial

ReNeuron Group Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of ReNeuron Group's Days Payable

For the Biotechnology subindustry, ReNeuron Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ReNeuron Group's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ReNeuron Group's Days Payable distribution charts can be found below:

* The bar in red indicates where ReNeuron Group's Days Payable falls into.

ReNeuron Group Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

ReNeuron Group's Days Payable for the fiscal year that ended in Mar. 2023 is calculated as

	Days Payable (A: Mar. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Mar. 2022 )	+	Accounts Payable (A: Mar. 2023 ))	/	count )	/	Cost of Goods Sold (A: Mar. 2023 )	*	Days in Period
=	( (0.734	+	0.319)	/	2 )	/	0	*	365
=	0.5265					/	0	*	365
=	N/A

ReNeuron Group's Days Payable for the quarter that ended in Sep. 2023 is calculated as:

	Days Payable (Q: Sep. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Mar. 2023 )	+	Accounts Payable (Q: Sep. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2023 )	*	Days in Period
=	( (0.319	+	3.657)	/	2 )	/	0	*	365 / 2
=	1.988					/	0	*	365 / 2
=	N/A

ReNeuron Group Days Payable Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

ReNeuron Group (LSE:RENE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (LSE:RENE) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

RNUGF:USA RENE.GB:UK RQE1:Germany

Address

Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY

Website

https://www.reneuron.com

ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.